Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ACRV logo ACRV
Upturn stock ratingUpturn stock rating
ACRV logo

Acrivon Therapeutics, Inc. Common Stock (ACRV)

Upturn stock ratingUpturn stock rating
$1.33
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: ACRV (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $11.17

1 Year Target Price $11.17

Analysts Price Target For last 52 week
$11.17 Target price
52w Low $1.05
Current$1.33
52w High $10

Analysis of Past Performance

Type Stock
Historic Profit -44.24%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 41.84M USD
Price to earnings Ratio -
1Y Target Price 11.17
Price to earnings Ratio -
1Y Target Price 11.17
Volume (30-day avg) 9
Beta 1.67
52 Weeks Range 1.05 - 10.00
Updated Date 08/29/2025
52 Weeks Range 1.05 - 10.00
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.24

Earnings Date

Report Date 2025-08-13
When -
Estimate -1.09
Actual -0.55

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -30.32%
Return on Equity (TTM) -47.88%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -92323993
Price to Sales(TTM) -
Enterprise Value -92323993
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.43
Shares Outstanding 31455600
Shares Floating 16683445
Shares Outstanding 31455600
Shares Floating 16683445
Percent Insiders 20.64
Percent Institutions 56.74

ai summary icon Upturn AI SWOT

Acrivon Therapeutics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Acrivon Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for cancer. Founded in 2009, it utilizes its proprietary proteomics-based platform, Acrivon Predictive Precision (APPi), to identify patients most likely to respond to specific drug candidates.

business area logo Core Business Areas

  • Drug Development: Focuses on the discovery and development of novel therapies for oncology.
  • Diagnostic Development: Develops companion diagnostics to identify patients likely to benefit from its therapies.
  • APPi Platform: Provides a proteomic screening platform that analyzes a patient's tumor sample to determine if they are likely to respond to the drug.

leadership logo Leadership and Structure

Dr. Peter Blume-Jensen serves as the President and CEO. The company has a management team with expertise in oncology drug development and diagnostics. It operates as a publicly traded biopharmaceutical company.

Top Products and Market Share

overview logo Key Offerings

  • ACRN-368: An investigational Chk1/2 inhibitor for the treatment of advanced cancers with specific genetic mutations. It's in clinical development. Competitors include other Chk1/2 inhibitors in development from companies like Merck and Novartis. Market share is currently 0 as it is pre-commercial.
  • ACRN-1000: A preclinical protein degrader targeting transcription factor involved in tumor cell growth. Competitors are companies developing similar PROTAC protein degradation technologies, such as Arvinas and C4 Therapeutics. Market share is currently 0 as it is pre-clinical.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive, with significant investment in cancer therapies. There's a growing trend towards precision medicine and targeted therapies.

Positioning

Acrivon is positioned as a precision medicine company leveraging its APPi platform to select patients most likely to respond to its drug candidates, aiming for improved efficacy and reduced toxicity.

Total Addressable Market (TAM)

The global oncology market is projected to reach hundreds of billions of dollars. Acrivon's focus on precision medicine positions it to capture a segment of this market by improving treatment outcomes and potentially reducing healthcare costs through patient selection.

Upturn SWOT Analysis

Strengths

  • Proprietary APPi platform for patient selection
  • Focus on precision medicine
  • Experienced management team
  • Novel drug candidates with potential for improved efficacy

Weaknesses

  • Limited number of clinical-stage assets
  • High cash burn rate typical of biotech companies
  • Reliance on successful clinical trial outcomes
  • Potential for competition from larger pharmaceutical companies

Opportunities

  • Partnerships with pharmaceutical companies
  • Expansion of APPi platform to other diseases
  • Successful clinical trial results leading to regulatory approval
  • Potential for acquisitions

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other cancer therapies
  • Economic downturn impacting funding

Competitors and Market Share

competitor logo Key Competitors

  • ARVN
  • MRK
  • NVS

Competitive Landscape

Acrivon faces competition from established pharmaceutical companies and other biotech companies in the oncology space. Its competitive advantage lies in its APPi platform, which aims to improve patient selection and drug efficacy. Acrivon has no market share as it currently does not have any commercial products.

Growth Trajectory and Initiatives

Historical Growth: Acrivon has focused on research and development, so it does not have a significant growth history yet.

Future Projections: Future growth depends on successful clinical trials and regulatory approvals of its drug candidates. Analyst estimates are highly variable due to the uncertainty of the biotech industry.

Recent Initiatives: Advancement of ACRN-368 and ACRN-1000 through clinical trials, expansion of APPi platform capabilities, and pursuit of strategic partnerships.

Summary

Acrivon Therapeutics is a promising biopharmaceutical company leveraging a proprietary technology platform for precision medicine. Currently its fundamentals are weak, and it faces significant risk due to dependence on clinical trial success and regulatory approvals. The company needs to look out for potential clinical trial failures, competition, and regulatory hurdles. Its strength lies in its APPi platform and novel drug candidates.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Acrivon Therapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters Watertown, MA, United States
IPO Launch date 2022-11-15
Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Dr. Peter Blume-Jensen M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 75
Full time employees 75

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.